Cabel wrote "So with low LDL being considered a good thing,... will it be possible to actually market Apabetalone for Diabetic patients with CVD and low LDL,..? Also will they analyse how many patients who ended up being in the low LDL group, that were also in the low eGFR group,...? So those who had low LDL and under 60 eGFR,...?"

All good questions that I don't have answers for. We discussed the low LDL-C issue before and some posters including myself threw out some hypotheses. However, we don't have enough information about the number of patients in each subgroup right now to really understand this right now. Perhaps the company will shed some light on this in the future.

BDAZ